

Philipp J Jost

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8355966/publications.pdf>

Version: 2024-02-01

80
papers

8,776
citations

236925

25
h-index

71685

76
g-index

85
all docs

85
docs citations

85
times ranked

14507
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. <i>Thrombosis and Haemostasis</i> , 2022, 122, 633-645.	3.4	7
2	Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2022, 126, 456-463.	6.4	15
3	The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner. <i>Oncogene</i> , 2022, 41, 1376-1382.	5.9	7
4	Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study. <i>Cancer Medicine</i> , 2022, 11, 3074-3083.	2.8	16
5	Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study. <i>Frontiers in Immunology</i> , 2022, 13, 840207.	4.8	7
6	Non-coding RNAs and ferroptosis: potential implications for cancer therapy. <i>Cell Death and Differentiation</i> , 2022, 29, 1094-1106.	11.2	48
7	MCL1 as putative target in pancreatoblastoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 265-272.	2.8	3
8	Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?. <i>Supportive Care in Cancer</i> , 2021, 29, 2171-2178.	2.2	12
9	Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	3.2	1
10	Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 699.	3.7	15
11	PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	7
12	Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity. <i>Cancers</i> , 2021, 13, 2492.	3.7	5
13	MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF. <i>Cell Death and Differentiation</i> , 2021, 28, 3235-3250.	11.2	9
14	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	9.4	125
15	In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets. <i>Nature Communications</i> , 2021, 12, 5655.	12.8	10
16	Trends and Patterns in the Public Awareness of Palliative Care, Euthanasia, and End-of-Life Decisions in 3 Central European Countries Using Big Data Analysis From Google: Retrospective Analysis. <i>Journal of Medical Internet Research</i> , 2021, 23, e28635.	4.3	4
17	Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN. <i>Leukemia Research</i> , 2021, 110, 106646.	0.8	2
18	Spinal Manifestation of Malignant Primary (PLB) and Secondary Bone Lymphoma (SLB). <i>Current Oncology</i> , 2021, 28, 3891-3899.	2.2	8

#	ARTICLE	IF	CITATIONS
19	Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 148, 331.	2.5	2
20	XIAP restrains TNF-driven intestinal inflammation and dysbiosis by promoting innate immune responses of Paneth and dendritic cells. <i>Science Immunology</i> , 2021, 6, eabf7235.	11.9	17
21	Regulation of Cell Death and Immunity by XIAP. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a036426.	5.5	47
22	Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis. <i>European Journal of Haematology</i> , 2020, 104, 125-137.	2.2	5
23	Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. <i>Cell Death and Disease</i> , 2020, 11, 875.	6.3	17
24	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. <i>Nature</i> , 2020, 588, 157-163.	27.8	90
25	Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naïve Patients with Resectable Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3496.	3.7	3
26	MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. <i>Nature Communications</i> , 2020, 11, 4527.	12.8	32
27	Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. <i>Leukemia</i> , 2020, 34, 1949-1953.	7.2	13
28	Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2020, 6, 1241.	7.1	111
29	Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes. <i>Journal of Hepatology</i> , 2020, 73, 1347-1359.	3.7	11
30	Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML. <i>Cancer Research</i> , 2020, 80, 2394-2406.	0.9	30
31	Response to tyrosine kinase inhibitors in myeloid neoplasms associated with <i>PCM1</i> , <i>JAK2</i> , <i>BCR</i> and <i>ETV6</i> fusion genes. <i>American Journal of Hematology</i> , 2020, 95, 824-833.		46
32	Abstract 821: Comprehensive genomic analysis of rare cancers: Results of the MASTER precision oncology trial of the German Cancer Consortium. , 2020, , .		0
33	TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP. <i>Cell Death and Disease</i> , 2019, 10, 700.	6.3	25
34	Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. <i>Experimental Hematology and Oncology</i> , 2019, 8, 9.	5.0	36
35	Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). <i>International Journal of Cancer</i> , 2019, 145, 2292-2303.	5.1	21
36	A step towards valid detection and quantification of lung cancer volume in experimental mice with contrast agent-based X-ray microtomography. <i>Scientific Reports</i> , 2019, 9, 1325.	3.3	17

#	ARTICLE	IF	CITATIONS
37	Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL2 and/or BIM. <i>European Journal of Haematology</i> , 2019, 102, 437-441.	2.2	18
38	XIAP deficiency in hematopoietic recipient cells drives donor T cell activation and GvHD in mice. <i>European Journal of Immunology</i> , 2019, 49, 504-507.	2.9	13
39	Necroinflammation emerges as a key regulator of hematopoiesis in health and disease. <i>Cell Death and Differentiation</i> , 2019, 26, 53-67.	11.2	13
40	An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor. <i>Blood</i> , 2019, 134, 2945-2945.	1.4	6
41	Abstract 468: Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies: Results from the MASTER trial of the German Cancer Consortium. , 2019, , .		0
42	Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 2944-2944.	1.4	2
43	Effect of ABCG2 , OCT1 , and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 266-271.	0.4	18
44	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	11.2	4,036
45	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DTK Molecularly Aided Stratification for Tumor Eradication Research Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	3.0	20
46	Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft. <i>BMC Nephrology</i> , 2018, 19, 106.	1.8	8
47	Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. <i>Oncotarget</i> , 2018, 9, 17270-17281.	1.8	18
48	A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. <i>Cancer Cell</i> , 2017, 32, 342-359.e10.	16.8	122
49	XIAP Loss Triggers RIPK3- and Caspase-8-Driven IL-1 β Activation and Cell Death as a Consequence of TLR-MyD88-Induced cIAP1-TRAF2 Degradation. <i>Cell Reports</i> , 2017, 20, 668-682.	6.4	112
50	Killing AML: RIPK3 leads the way. <i>Cell Cycle</i> , 2017, 16, 3-4.	2.6	3
51	Abstract LB-287: Identification of patients at risk for tumor predisposition syndromes based on the evaluation of sporadic cancer exome sequencing data: experiences from the NCT/DTK MASTER program. , 2017, , .		0
52	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. <i>Cancer Cell</i> , 2016, 30, 75-91.	16.8	144
53	CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling. <i>Cell Reports</i> , 2016, 14, 2846-2858.	6.4	128
54	Loss of XIAP facilitates switch to TNF α -induced necroptosis in mouse neutrophils. <i>Cell Death and Disease</i> , 2016, 7, e2422-e2422.	6.3	69

#	ARTICLE	IF	CITATIONS
55	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive Bâ€cell lymphoma. <i>EMBO Molecular Medicine</i> , 2016, 8, 851-862.	6.9	50
56	Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. <i>Leukemia</i> , 2016, 30, 1520-1530.	7.2	26
57	A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML. <i>Blood</i> , 2016, 128, 3099-3099.	1.4	1
58	Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure. <i>Blood</i> , 2016, 128, 4297-4297.	1.4	5
59	RIPK3-dependent cell death and inflammasome activation in FLT3-ITD expressing LICs. <i>Oncotarget</i> , 2016, 7, 57483-57484.	1.8	7
60	Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms. <i>Blood</i> , 2016, 128, 3114-3114.	1.4	0
61	Evasion of Necroptosis and Inflammasome Activation Promotes Myeloid Leukemogenesis. <i>Blood</i> , 2016, 128, 2856-2856.	1.4	1
62	XIAP as a regulator of inflammatory cell death: the TNF and RIP3 angle. <i>Molecular and Cellular Oncology</i> , 2015, 2, e964622.	0.7	5
63	cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. <i>Blood</i> , 2014, 123, 2562-2572.	1.4	145
64	Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature. <i>Experimental Hematology and Oncology</i> , 2014, 3, 29.	5.0	3
65	The Acute Transcriptomic and Proteomic Response of HC-04 Hepatoma Cells to Hepatocyte Growth Factor and its Implications for Plasmodium falciparum Sporozoite Invasion. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1153-1164.	3.8	21
66	XIAP Restricts TNF- and RIP3-Dependent Cell Death and Inflammasome Activation. <i>Cell Reports</i> , 2014, 7, 1796-1808.	6.4	210
67	A Mouse Model for XLP-2 Disease Uncovers a Critical Function for IL-1beta and TNF in Driving Hyper-Inflammation. <i>Blood</i> , 2014, 124, 1403-1403.	1.4	0
68	Evidence of an autoregulatory mechanism of regional bone blood flow at hypotension. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2013, 133, 1233-1241.	2.4	3
69	Diseaseâ€causing mutations in the <sc>XIAP</sc> <sc>BIR</sc> 2 domain impair <sc>NOD</sc> 2â€dependent immune signalling. <i>EMBO Molecular Medicine</i> , 2013, 5, 1278-1295.	6.9	137
70	Local cooling reduces regional bone blood flow. <i>Journal of Orthopaedic Research</i> , 2013, 31, 1820-1827.	2.3	9
71	Fas death receptor signalling: roles of Bid and XIAP. <i>Cell Death and Differentiation</i> , 2012, 19, 42-50.	11.2	299
72	The Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate Immunity. <i>Molecular Cell</i> , 2012, 46, 746-758.	9.7	336

#	ARTICLE	IF	CITATIONS
73	Cancer caused by too much apoptosis-An intriguing contradiction?. Hepatology, 2010, 51, 1110-1112.	7.3	4
74	Mcl-1 Is Essential for Germinal Center Formation and B Cell Memory. Science, 2010, 330, 1095-1099.	12.6	196
75	Fatal Hepatitis Mediated by Tumor Necrosis Factor TNF α Requires Caspase-8 and Involves the BH3-Only Proteins Bid and Bim. Immunity, 2009, 30, 56-66.	14.3	128
76	XIAP discriminates between type I and type II FAS-induced apoptosis. Nature, 2009, 460, 1035-1039.	27.8	421
77	The Many Roles of FAS Receptor Signaling in the Immune System. Immunity, 2009, 30, 180-192.	14.3	800
78	Bcl10/Malt1 Signaling Is Essential for TCR-Induced NF- κ B Activation in Thymocytes but Dispensable for Positive or Negative Selection. Journal of Immunology, 2007, 178, 953-960.	0.8	24
79	Aberrant NF- κ B signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood, 2007, 109, 2700-2707.	1.4	376
80	Very Severe Iron-Deficiency Anemia in a Patient with Celiac Disease and Bulimia Nervosa: A Case Report. International Journal of Hematology, 2005, 82, 310-311.	1.6	11